Neogen (NEOG) Stock Price, News & Analysis

Company Overview

Neogen Corporation is a global provider of food and animal safety products, offering a broad portfolio of diagnostic and testing solutions. Headquartered in Lansing, Michigan, the company develops and manufactures tests designed to detect foodborne pathogens, allergens and toxins in food, beverage and environmental samples. Since its founding in 1982, Neogen has focused on delivering rapid, accurate and user‐friendly assays to food processors, grain handlers and quality laboratories around the world.

In the food safety arena, Neogen’s product lineup includes immunoassay kits, molecular diagnostics and enrichment media for pathogens such as Salmonella, Listeria and E. coli, as well as methods for mycotoxin and allergen detection. These offerings are complemented by software, instrumentation and training services that help customers maintain regulatory compliance and optimize their quality control processes. The company regularly invests in research and development to expand its testing capabilities and to address emerging contaminants in the food supply chain.

Beyond food testing, Neogen serves the animal safety market with an array of products for livestock and companion animals. Its animal safety segment provides medicated and non‐medicated feed additives, premixes, disinfectants and veterinary instruments. These products support animal health and productivity in industries such as dairy, poultry, swine and aquaculture. Neogen also supplies nutritional feed supplements and environmental hygiene solutions that help producers manage disease risk and improve overall herd performance.

Neogen operates through a network of subsidiaries and distribution partners in more than 100 countries across North America, Europe, Asia and Latin America. The company is led by James Herbert, who serves as president and chief executive officer, and emphasizes a commitment to innovation, quality and customer support. By combining proprietary technologies with global reach, Neogen aims to address critical safety challenges in the food and animal health markets.

Key Stats

• Today's Range: $5.46 to $5.69
• 50-Day Range: $4.65 to $5.75
• 52-Week Range: $3.87 to $17.18
• Volume: 22.19 million shs
• Average Volume: 5.56 million shs
• Market Capitalization: $1.21 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.33
• Consensus Rating: Hold

Neogen Stock Analysis - MarketRank™

Neogen scored higher than 65% of companies evaluated by MarketBeat, and ranked 355th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Hold

Consensus Rating

Neogen has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.

Upside Potential

Neogen has a consensus price target of $8.33, representing about 49.1% upside from its current price of $5.59.

Amount of Analyst Coverage

Neogen has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 28.95%

Earnings Growth

Earnings for Neogen are expected to grow by 28.95% in the coming year, from $0.38 to $0.49 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Neogen is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Neogen is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Neogen has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.55% of the float of Neogen has been sold short.

Short Interest Ratio / Days to Cover

Neogen has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Neogen has recently increased by 7.49%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Neogen does not currently pay a dividend.

Dividend Growth

Neogen does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.55% of the float of Neogen has been sold short.

Short Interest Ratio / Days to Cover

Neogen has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Neogen has recently increased by 7.49%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.93

News Sentiment

Neogen has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Neogen this week, compared to 22 articles on an average week.

Search Interest

10 people have searched for NEOG on MarketBeat in the last 30 days.

MarketBeat Follows

Only 2 people have added Neogen to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Neogen insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.55% of the stock of Neogen is held by insiders.

Percentage Held by Institutions

96.73% of the stock of Neogen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NEOG Stock Analysis - Frequently Asked Questions

How have NEOG shares performed this year?

Neogen's stock was trading at $12.14 at the start of the year. Since then, NEOG shares have decreased by 54.0% and is now trading at $5.59.

How were Neogen's earnings last quarter?

Neogen Corporation (NASDAQ:NEOG) released its quarterly earnings data on Wednesday, April, 9th. The company reported $0.10 earnings per share for the quarter, missing the consensus estimate of $0.12 by $0.02. Neogen's quarterly revenue was down 3.4% on a year-over-year basis.
Read the conference call transcript.

When did Neogen's stock split?

Neogen's stock split before market open on Tuesday, January 2nd 2018.The 4-3 split was announced on Friday, December 8th 2017. The newly created shares were distributed to shareholders after the closing bell on Friday, December 29th 2017. An investor that had 100 shares of stock prior to the split would have 133 shares after the split.

How do I buy shares of Neogen?

Shares of NEOG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Neogen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Neogen investors own include NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX) and Visa (V).

Company Calendar

• Last Earnings: 4/09/2025
• Today: 9/29/2025
• Next Earnings (Estimated): 10/09/2025
• Fiscal Year End: 5/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Health Care Supplies
• Current Symbol: NASDAQ:NEOG
• CIK: 711377
• Web: www.neogen.com
• Phone: (517) 372-9200
• Fax: 517-372-2006
• Employees: 2,110
• Year Founded: 1982

Price Target and Rating

• Average Price Target for Neogen: $8.33
• High Price Target: $10.00
• Low Price Target: $5.00
• Potential Upside/Downside: +49.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 14.67
• P/E Growth: N/A
• Net Income: -$1.09 billion
• Net Margins: -122.06%
• Pretax Margin: -126.65%
• Return on Equity: 2.39%
• Return on Assets: 1.57%

Debt

• Debt-to-Equity Ratio: 0.42
• Current Ratio: 3.32
• Quick Ratio: 2.22

Sales & Book Value

• Annual Sales: $894.66 million
• Price / Sales: 1.35
• Cash Flow: $5.69 per share
• Price / Cash Flow: 0.98
• Book Value: $9.54 per share
• Price / Book: 0.58

Miscellaneous

• Outstanding Shares: 217,210,000
• Free Float: 216,010,000
• Market Cap: $1.21 billion
• Optionable: Optionable
• Beta: 1.84